Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
309.80
+0.74 (0.24%)
After Hours: 309.80 0.00 (0.00%)
Nov 22, 4:38PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 307.15 - 311.11
52 week 244.28 - 348.84
Open 308.91
Vol / Avg. 733,319.00/1.42M
Mkt cap 65.52B
P/E 19.00
Div/yield     -
EPS 16.31
Shares 211.48M
Beta 0.72
Inst. own 92%
Nov 4, 2017
Biogen Inc. - Special Call
Nov 2, 2017
Biogen Inc. - Special Call
Oct 24, 2017
Q3 2017 Biogen Inc Earnings Release
Oct 24, 2017
Q3 2017 Biogen Inc Earnings Call - Webcast
Sep 11, 2017
Biogen Inc at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 39.84% 32.28%
Operating margin 53.72% 44.99%
EBITD margin - 55.41%
Return on average assets 21.94% 17.44%
Return on average equity 40.24% 34.42%
Employees 7,400 -
CDP Score - B

Address

225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Michel Vounatsos Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Gregory F. Covino Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Ginger Gregory Ph.D. Chief Human Resource Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Michael D. Ehlers M.D., Ph.D. Executive Vice President, Head - Research and Development
Age: 48
Bio & Compensation  - Reuters
Chirfi Guindo Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 54
Bio & Compensation  - Reuters
Jean-Paul Kress M.D. Executive Vice President, President - International and Head of Global Therapeutic Operations
Age: 51
Bio & Compensation  - Reuters